2025 年 42 巻 3 号 p. 342-346
We have various clinical problems to treat neuromyelitis optica spectrum disorder (NMOSD) and myelin–oligodendrocyte glycoprotein antibody–associated disease (MOGAD) such as health insurance adaptation, selection and adverse effects of therapeutic agents, and discrepancy between hypothetical pathomechanism and therapeutic efficacy. To solve these issues, we have established Japanese NMOSD/MOGAD Registry. We expect that this registry can accelerate clinical research, drug development, and tailor–made therapy in NMOSD and MOGAD by collecting and analyzing real world data.
